[pending] POTASSIUM CHLORIDE (POTASSIUM CHLORIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0180-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq
The recalled product
- Product
- POTASSIUM CHLORIDE (POTASSIUM CHLORIDE)
- Brand
- POTASSIUM CHLORIDE
- Manufacturer
- Otsuka ICU Medical LLC
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 1030613
- Exp Date: 09/30/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · POTASSIUM CHLORIDE
- SeverePotassium Chloride Injection Strength Mislabeled on Packaging Overwrap
FDA (Drugs) · 2025-03-19
- SeverePotassium Chloride Injection Recalled: Overwrap Labeling Shows Incorrect Strength
FDA (Drugs) · 2025-03-19
- HighPotassium Chloride Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-02-12
- SeverePotassium Chloride Extended-Release Capsules Recalled Over Failed Dissolution
FDA (Drugs) · 2024-08-07
- HighPrescription Potassium Chloride Extended-Release Capsules Recalled for Manufacturing Deviations
FDA (Drugs) · 2024-07-24
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27